Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$68.04 USD

68.04
1,959,674

-0.08 (-0.12%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $68.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

Are Medical Stocks Lagging AC Immune (ACIU) This Year?

Here is how AC Immune (ACIU) and Exact Sciences (EXAS) have performed compared to their sector so far this year.

Exact Sciences (EXAS) Just Overtook the 20-Day Moving Average

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises

Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.

Urmimala Biswas headshot

MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More

MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.

Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?

Here is how Exact Sciences (EXAS) and Anebulo Pharmaceuticals, Inc. (ANEB) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights Adobe, S&P Global, Arista Networks, Cincinnati Financial and Exact Sciences

Adobe, S&P Global, Arista Networks, Cincinnati Financial and Exact Sciences are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Adobe, S&P Global & Arista Networks

Today's Research Daily features new research reports on 12 major stocks, including Adobe Inc. (ADBE), S&P Global Inc. (SPGI) and Arista Networks, Inc. (ANET).

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs

Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.

Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH

Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.

Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View

Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.

Here's What Key Metrics Tell Us About Exact Sciences (EXAS) Q2 Earnings

Although the revenue and EPS for Exact Sciences (EXAS) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 10% and 3.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.